Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

NCT02049294 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.

NCT NCT02049294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02049294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
Lead sponsor
McMaster University
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2014
Completion date
September 30, 2017
Enrollment
11 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic bronchitis, steroid and/or prednisone dependent asthma